Barclays has maintained FY22 real GDP growth forecast at 11 per cent y-o-y - at least for now, cautioning against the downside risk if the covid-19 lockdowns and night curfews are tightened further
This is a sharp reversal in fortunes as till mid-February India was among the best-performing markets, with returns in excess of 10 per cent
Going ahead, analysts at ICICI Securities expect consolidation across the industry with market share gains for larger incumbents across real estate asset classes
Among the losers on the Nifty were Tata Motors, Adani Ports, IndusInd Bank, Bajaj Finance, UPL, SBI, Hindalco, and Shree Cement, down in the range of 5.6 per cent to 10 per cent
We caught up with Gaurav Dua and Aamar Deo Singh to understand where are the markets headed, what should be the investment strategy and which sectors and stocks look good to park one's money in
Index heavyweights such as Reliance Industries, HDFC Bank, HDFC, ICICI Bank, SBI, Bajaj Finance, TCS, and L&T declined up to 7 per cent.
Broader markets, on the other hand, faced an even severe blow with the S&P BSE MidCap and SmallCap indices dropping 5 per cent each
This is the third vaccine approved by India, after Covishield and Covaxin.
While a value of Rs 74-74.5/$ looks fair, one can never tell. The RBI may have to intervene if the rupee crosses the 75 mark and edges upwards
The debt repayment will result in significant savings in the finance cost, it said
The stock has rallied 36 per cent in the past three trading days
Trends in client budget, vertical wise trends, growth in digital technologies, margin trajectory, deal pipeline and long term IT trend will be among the key things to watch in Q4 results of TCS
Solara Active and Aurore Life Sciences' amalgamation would create one of the largest API players in the industry
If the Nifty IT index manages to sustain above 27,200 levels, the upside bias may see a rally towards 27,800-mark in the upcoming sessions
Investors' wealth tumbled by Rs 6,86,708.74 crore in morning trade on Monday following massive losses in the equity market as sentiments remained muted amid increasing Covid-19 cases in the country
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
The domestic unit slipped to 75.13 versus the US dollar, a level seen in August last year
India recorded a massive surge of 1.69 lakh Covid-19 cases in the last 24 hours
The buyback could be worth Rs 10,000 - 12000 crore (around 2 per cent of market cap) at a price of Rs 1650- 1670 per share, a media report said
Shakti Pumps (India) on Sunday said it is planning business expansion next year as the company eyes a bigger share in the Centre's PM-KUSUM scheme of solar water pumps